Efficacy and safe of Ledipasvir/Sofosbuvir with Ribavirin in Patients who failed Daclatasvir/Asunaprevir with chronic hepatitis C-multicenter,pilot study
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000021969
- Lead Sponsor
- Hiroshima liver study group
- Brief Summary
The overall SVR12 rate was 86.7% (26/30). Large decreases in mean log10 HCV RNA levels were observed in patients without cirrhosis, and the SVR12 rate for these patients was 100% (12/12). In cases of cirrhosis, SVR12 rate was 72.2%(13/18) .The common factors in treatment failure cases were the presence of liver cirrhosis and both NS5A L31M/I and Y93H RAVs. The frequency of RAVs did not change before and after treatment among patients who relapsed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1)Patients with serious renal disease(eGFR<30mL/min/1.73m2) or dialysis 2)Patients with haemoglobinopathies (thalassemia, sickle cell anemia) 3)Decompenstated liver cirrhosis 4)HCC, malignat tumor 5)Patients with Hb less than 10 g/dl. 6)Pregnant or lactating women and women who may be pregnant 7)Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method